
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Montreal -- Researchers here say that a new oral calcineurininhibitor called ISA247 is an effective treatment for chronicplaque psoriasis and has fewer risks than the commonly usedcyclosporine.